- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03642106
Unidos Against ATOD Use Intervention Trial (TWC)
Reducing Alcohol, Tobacco, and Drug Use Among Latino Immigrant Youth: A Preliminary Test of the ¡Unidos Se Puede! Program
Adolescent alcohol tobacco and drug (ATOD) use is a major public health concern, with rates for Latino middle school youth higher than other ethnic groups. One well-established precursor of adolescent ATOD use is psychosocial stress. The proposed project examines the preliminary efficacy of Unidos to decrease ATOD use among Latino youth in new settlement areas. The goals of this efficacy trial will be achieved by accomplishing two specific aims: (1) Evaluate the potential of the intervention to delay the initiation into or reduce ATOD use among Latino youth who are 1st to 2nd generation immigrants; and (2) Evaluate the intervention's ability to strengthen known protective factors against ATOD use among adolescents-specifically child personal agency and parent-child, peer, and school relationships.
The study's primary hypothesis is: The Unidos Se Puede program will delay initiation of ATOD use of current non-users and reduce use among current users.
Study Overview
Detailed Description
Adolescent alcohol tobacco and drug (ATOD) use is a major public health concern, with rates for Latino middle school youth higher than other ethnic groups. One well-established precursor of adolescent ATOD use is psychosocial stress. The overall aim of this project is to test the efficacy of a culturally appropriate psychosocial program to prevent or reduce ATOD use among Latino immigrant youth. The intervention consists of: (1) encouraging parental involvement in child schooling, general parenting skills, and coping strategies ; (2) fostering child social emotional learning (SEL) through assigning a near-peer success coach to help develop critical thinking, problem solving, and goal setting skills; and (3) promoting positive peer affiliations through participation in regular activities that facilitate bonding to prosocial institutions.
The specific aims are:
(1) Evaluate the potential of the intervention to delay the initiation into or reduce ATOD use among Latino youth who are 1st to 2nd generation immigrants; and (2) Evaluate the intervention's ability to strengthen known protective factors against ATOD use among adolescents-specifically child personal agency and parent-child, peer, and school relationships.
The study's primary hypothesis is: The Unidos Se Puede program will delay initiation of ATOD use of current non-users and reduce use among current users.
To accomplish these aims, we propose an attention placebo randomized control trial. For this trial, we will recruit a sample of youth and their parents (N=120 dyads) from a random sample of Latino 6th and 7th grade students in Tulsa Public Schools. Those meeting the inclusion/exclusion criteria and agreeing to participate will provide baseline data before being randomly assigned to either the treatment or control condition (n=60 dyads each). Participants will be followed for 12 months post-baseline, during which time we will collect psychosocial measures annually near the end of each school year (May to June). The study will collect psychosocial measures from parents and youth.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Ronald B Cox, PhD
- Phone Number: 4057449938
- Email: r.cox@okstate.edu
Study Contact Backup
- Name: Isaac Washburn, PhD
- Phone Number: 4057443683
- Email: isaac.washburn@okstate.edu
Study Locations
-
-
Oklahoma
-
Tulsa, Oklahoma, United States, 74106
- Recruiting
- Oklahoma State University-Tulsa
-
Contact:
- Isaac Washburn, PhD
- Phone Number: 4057443683
- Email: isaac.washburn@okstate.edu
-
Contact:
- Ronald B Cox, PhD
- Phone Number: 405-744-9938
- Email: r.cox@okstate.edu
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Self-identified as Latino (Hispanic),
- Spanish as the primary language spoken in home,
- Enrolled in 6th or 7th grade in public school at one of the target sites.
Exclusion Criteria:
- Currently undergoing mental health treatment,
- Not eligible to take end of year examinations due to cognitive limitations.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Unidos Se Puede
Unidos Se Puede: consists of 5-weekly Family Workshops, 6 monthly booster sessions, 10-months success coaching, adolescent group activities and will be compared to an attention placebo control.
|
The intervention consists of: (1) encouraging parental involvement in child schooling, general parenting skills, and coping strategies ; (2) fostering child social emotional learning (SEL) through assigning a near-peer success coach to help develop critical thinking, problem solving, and goal setting skills; and (3) promoting positive peer affiliations through participation in regular activities that facilitate bonding to prosocial institutions.
Other Names:
|
Placebo Comparator: Attention placebo control
Placebo consists of after school club for youth.
|
The intervention consists of: (1) encouraging parental involvement in child schooling, general parenting skills, and coping strategies ; (2) fostering child social emotional learning (SEL) through assigning a near-peer success coach to help develop critical thinking, problem solving, and goal setting skills; and (3) promoting positive peer affiliations through participation in regular activities that facilitate bonding to prosocial institutions.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in past 30-day ATOD use (alcohol, tobacco, marijuana)
Time Frame: Baseline and 12 months post-baseline
|
The ATOD outcome measure creates a single index of use by summing youth report of the frequency of their use during the past 30 days for each of the following substance: alcohol, tobacco and marijuana.
|
Baseline and 12 months post-baseline
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Ronald B Cox, PhD, Oklahoma State University
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- IRB-21-290
- 5P20GM109097-02 (U.S. NIH Grant/Contract)
- 1R15DA049232-01 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Substance Use
-
Medical University of South CarolinaNational Institute on Drug Abuse (NIDA)RecruitingSubstance Use | Substance Use Disorders | Cannabis Use | Alcohol Use, UnspecifiedUnited States
-
Woebot HealthNational Institute on Drug Abuse (NIDA); Stanford UniversityCompletedSubstance Use Disorders | Alcohol Use Disorder (AUD)United States
-
Icahn School of Medicine at Mount SinaiNational Institute on Drug Abuse (NIDA)RecruitingSubstance Use Disorder | Cocaine Use DisorderUnited States
-
Emory UniversityNational Institute on Drug Abuse (NIDA); Georgia Institute of Technology; CUNYCompletedSubstance-Related Disorders | Substance Abuse, Intravenous | Substance Use Disorders | Opioid Use | Substance Abuse | Opioid-use Disorder | Opioid Use Disorder, Severe | Substance WithdrawalUnited States
-
Woebot HealthStanford UniversityCompletedSubstance Use Disorders | Alcohol Use Disorder (AUD)United States
-
University of MichiganNational Institute on Alcohol Abuse and Alcoholism (NIAAA)RecruitingSubstance Use | Substance Use Disorders | Substance DependenceUnited States
-
Wake Forest University Health SciencesNational Institute on Drug Abuse (NIDA)RecruitingSubstance Use | Opioid Use | Drug Use | Substance MisuseUnited States
-
Istanbul UniversityCompletedSubstance Use | Substance Use Disorders | Substance AbuseTurkey
-
Centre for Addiction and Mental HealthUniversity of Missouri, St. LouisCompletedSubstance Use Disorders | Alcohol Use DisorderCanada
-
Medical University of South CarolinaNational Institute on Drug Abuse (NIDA)CompletedPTSD | Alcohol Use Disorders | Substance Use DisordersUnited States
Clinical Trials on Unidos Se Puede
-
University of ArizonaEl Rio Community Health Center; Pima County Health Department; Yuma County Health... and other collaboratorsRecruitingChronic Disease | Community Health WorkersUnited States
-
Fatebenefratelli HospitalFederico II University; Federal University of Rio Grande do Sul; Royal Brompton... and other collaboratorsRecruitingCoronary Artery Disease | Heart Failure | Aortic Valve Disease | Pulmonary Arterial Hypertension | Tetralogy of Fallot | Hypertrophic Cardiomyopathy | Athletes HeartItaly
-
Boston VA Research Institute, Inc.Agency for Healthcare Research and Quality (AHRQ)Completed
-
IDRIRockefeller UniversityCompleted
-
National Institute of Allergy and Infectious Diseases...Completed
-
University of California, San FranciscoCompletedExperimental Condition TCT | Controlled Condition CGUnited States
-
IDRIBill and Melinda Gates FoundationCompletedVisceral LeishmaniasisUnited States
-
MedReliefCompletedDiabetic Peripheral NeuropathyUnited States
-
Boehringer IngelheimCompleted